Marshall Wace LLP acquired a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 290,734 shares of the company's stock, valued at approximately $4,780,000. Marshall Wace LLP owned 0.54% of Upstream Bio as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also modified their holdings of the business. US Bancorp DE acquired a new stake in shares of Upstream Bio during the fourth quarter worth about $27,000. Legal & General Group Plc purchased a new stake in shares of Upstream Bio in the fourth quarter valued at about $28,000. Summit Investment Advisors Inc. purchased a new stake in shares of Upstream Bio in the fourth quarter valued at about $30,000. Corebridge Financial Inc. purchased a new stake in shares of Upstream Bio in the fourth quarter valued at about $142,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of Upstream Bio in the fourth quarter valued at about $149,000.
Upstream Bio Trading Up 3.1 %
NASDAQ UPB traded up $0.28 during trading hours on Wednesday, hitting $9.26. 189,688 shares of the stock were exchanged, compared to its average volume of 323,473. Upstream Bio, Inc. has a 12-month low of $5.14 and a 12-month high of $29.46. The stock has a 50-day moving average of $7.90 and a 200 day moving average of $14.37.
Upstream Bio Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Read More
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
